• Title of article

    Construction and Stable Expression of a Truncated Human Receptor Tyrosine Kinase Ror1 (Ror1-ECD)

  • Author/Authors

    Forouzesh، Flora نويسنده , , Shakeri Tabarian، Samira نويسنده Department of Antigen and Antibody Engineering, Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR , , Emami، Shaghayegh نويسنده Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR , , Jeddi Tehrani]، Mahmood نويسنده , , Hadavi، Reza نويسنده Department of Antibody-Antigen Engineering, Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran , , Rabbani، Hodjattallah نويسنده Immune and Gene Therapy Laboratory, CCK, Karolinska University Hospital Solna Department of Antigen and Antibody Engineering, Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR ,

  • Issue Information
    فصلنامه با شماره پیاپی 12 سال 2012
  • Pages
    5
  • From page
    41
  • To page
    45
  • Abstract
    Expression of receptor tyrosine kinase Ror1 in a wide variety of cancers has emerged as a new era focusing on targeting this receptor in cancer therapy. Our preliminary re-sults indicate the presence of a truncated transcript of Ror1 in tumor cells. The trun-cated Ror1 encompasses extracellular and transmembrane domains, lacking catalytic kinase domain (Ror1-ECD). As enzyme activity is highly dependent on the catalytic domain, we were wondering how this transcript and its encoded protein could play a possible role in tumorigenesis. To understand the function of this truncated transcript and whether or not the encoded protein translocates to the cell surface, we construct-ed a mammalian expression vector containing exon 1 to exon 8 of human Ror1 gene as a model system. The encoded protein by this construct covers the entire extracellular and transmembrane domains of Ror1. The Chinese Hamster Ovary Cell line (CHO) was used for transfection. Our results showed that this construct could express Ror1-ECD at protein level and also the protein could effectively translocate to the surface of transfected cells. Such model may suggest that a proportion of Ror1 molecules ex-pressed by tumor cells are not full-length Ror1. This notion may be considered when applying flow cytometry using antibodies against Ror1 for screening of tumor cells in order to avoid any miscalculation in the number of Ror1 molecules expressed by tumor cells. Furthermore, such expression may bring about assumptions on functional roles of Ror1-ECD in tumorigenesis, which requires extensive functional studies.
  • Journal title
    AJMB Avicenna Journal of Medical Biotechnology
  • Serial Year
    2012
  • Journal title
    AJMB Avicenna Journal of Medical Biotechnology
  • Record number

    1982933